Anti-diabetic combinations

• US 20070172525A1
• Filed: 03/15/2007
• Published: 07/26/2007
• Est. Priority Date: 03/15/2007
• Status: Abandoned Application

• Current Assignee: Nectid Inc. (Protect Pharmaceutical Corporation)
• Original Assignee: Nectid Inc. (Protect Pharmaceutical Corporation)
• Inventors: Sesha, Ramesh
• Application Number:
  US11/724,486
• Publication Number:
  US 20070172525A1
• Time in Patent Office: Days
• US Class Current: 424/468
• CPC Class Codes: A61K 31/155 Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
• CPC Class Codes: A61K 31/41 having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
• CPC Class Codes: A61K 9/1635 obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• CPC Class Codes: A61K 9/2077 Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
• CPC Class Codes: A61K 9/209 containing drug in at least two layers or in the core and in at least one outer layer
• CPC Class Codes: A61K 9/2866 Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Abstract

This invention a pharmaceutical composition comprising a DPP inhibitor and a slow release biguanide. The invention further discloses a method of administering a combination comprising a DPP inhibitor and a slow release biguanide to a mammal in need of thereof.

Claims

1. A pharmaceutical composition comprising a slow release biguanide and a DPP4 inhibitor wherein the said composition comprising:

a) Slow release core comprising a biguanide and at least one pharmaceutically acceptable excipient, b) An immediate release coat comprising a DPP4 inhibitor

2. A pharmaceutical composition of claim 1 wherein the DPP4 inhibitor is an entity that inhibits dipeptidyl peptidase IV protease.

3. A pharmaceutical composition of claim 1 wherein the biguanide is selected from comprising metformin, phenformin and buformin or their pharmaceutically equivalent salts or derivatives

4. A pharmaceutical composition of claim 1 wherein the DPP4 inhibitor is selected from a group comprising Sitagliptin, Vildagliptin, Saxagliptin, SYR 522, PHX1149, GRC-8200 and SSR-162369

9. A pharmaceutical composition of claim 1 wherein at least 95% of the DPP4 inhibitor is released within 120 minutes

10. A pharmaceutical composition according to claim 1 wherein the excipient is selected from a group comprising an adjuvant, a preservative, an antioxidant, a thickening agent, a chelating agent, an antifungal agent, an antibacterial agent, an isotonic agent, a flavoring agent, a sweetening agent, an anti-foaming agent, a colorant, a diluent, a moistening agent, a parietal cell activator, or a combination of thereof

5. A method of administering a pharmaceutical composition comprising a slow release biguanide and a DPP4 inhibitor wherein the said composition comprising:

a) Slow release core comprising a biguanide and at least one pharmaceutically acceptable excipient, b) An immediate release coat comprising a DPP4 inhibitor

6. A method of administration of claim 5, wherein the biguanide is selected from comprising metformin, phenformin and buformin or their pharmaceutically equivalent salts or derivatives

7. A method of administration of claim 5, wherein the DPP4 inhibitor is an entity that inhibits dipeptidyl peptidase IV protease.

8. A method of administration of claim 7, wherein the DPP4 inhibitor is selected from a group comprising Sitagliptin, Vildagliptin, Saxagliptin, SYR 522, PHX1149, GRC-8200 and SSR-162369